156 related articles for article (PubMed ID: 19225040)
1. Different inhibitory effects in rat and human carboxylesterases.
Takahashi S; Katoh M; Saitoh T; Nakajima M; Yokoi T
Drug Metab Dispos; 2009 May; 37(5):956-61. PubMed ID: 19225040
[TBL] [Abstract][Full Text] [Related]
2. Conclusive identification of the oxybutynin-hydrolyzing enzyme in human liver.
Sato Y; Miyashita A; Iwatsubo T; Usui T
Drug Metab Dispos; 2012 May; 40(5):902-6. PubMed ID: 22293119
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of carboxylesterases 1 and 2 plays an important role in prodrug metabolism in immunological liver injury rats.
Zhang C; Xu Y; Gao P; Lu J; Li X; Liu D
Int Immunopharmacol; 2015 Feb; 24(2):153-158. PubMed ID: 25499727
[TBL] [Abstract][Full Text] [Related]
4. Identification of carboxylesterases expressed in rat intestine and effects of their hydrolyzing activity in predicting first-pass metabolism of ester prodrugs.
Liu D; Gao J; Zhang C; Ren X; Liu Y; Xu Y
Pharmazie; 2011 Nov; 66(11):888-93. PubMed ID: 22204136
[TBL] [Abstract][Full Text] [Related]
5. Presence and inter-individual variability of carboxylesterases (CES1 and CES2) in human lung.
Gabriele M; Puccini P; Lucchi M; Vizziello A; Gervasi PG; Longo V
Biochem Pharmacol; 2018 Apr; 150():64-71. PubMed ID: 29407485
[TBL] [Abstract][Full Text] [Related]
6. Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase.
Shimizu M; Fukami T; Nakajima M; Yokoi T
Drug Metab Dispos; 2014 Jul; 42(7):1103-9. PubMed ID: 24751575
[TBL] [Abstract][Full Text] [Related]
7. In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities.
Fukami T; Takahashi S; Nakagawa N; Maruichi T; Nakajima M; Yokoi T
Drug Metab Dispos; 2010 Dec; 38(12):2173-8. PubMed ID: 20810539
[TBL] [Abstract][Full Text] [Related]
8. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.
Sanghani SP; Quinney SK; Fredenburg TB; Davis WI; Murry DJ; Bosron WF
Drug Metab Dispos; 2004 May; 32(5):505-11. PubMed ID: 15100172
[TBL] [Abstract][Full Text] [Related]
9. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions.
Slatter JG; Su P; Sams JP; Schaaf LJ; Wienkers LC
Drug Metab Dispos; 1997 Oct; 25(10):1157-64. PubMed ID: 9321519
[TBL] [Abstract][Full Text] [Related]
10. Allosteric kinetics of human carboxylesterase 1: species differences and interindividual variability.
Takahashi S; Katoh M; Saitoh T; Nakajima M; Yokoi T
J Pharm Sci; 2008 Dec; 97(12):5434-45. PubMed ID: 18383336
[TBL] [Abstract][Full Text] [Related]
11. Characterization of recombinant human carboxylesterases: fluorescein diacetate as a probe substrate for human carboxylesterase 2.
Wang J; Williams ET; Bourgea J; Wong YN; Patten CJ
Drug Metab Dispos; 2011 Aug; 39(8):1329-33. PubMed ID: 21540359
[TBL] [Abstract][Full Text] [Related]
12. Difference in substrate specificity of carboxylesterase and arylacetamide deacetylase between dogs and humans.
Yoshida T; Fukami T; Kurokawa T; Gotoh S; Oda A; Nakajima M
Eur J Pharm Sci; 2018 Jan; 111():167-176. PubMed ID: 28966098
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the inhibitory effects of antihypertensive drugs on human carboxylesterase in vitro.
Yanjiao X; Chengliang Z; Xiping L; Tao W; Xiuhua R; Dong L
Drug Metab Pharmacokinet; 2013; 28(6):468-74. PubMed ID: 23648675
[TBL] [Abstract][Full Text] [Related]
14. In vitro evaluation of the inhibitory potential of pharmaceutical excipients on human carboxylesterase 1A and 2.
Zhang C; Xu Y; Zhong Q; Li X; Gao P; Feng C; Chu Q; Chen Y; Liu D
PLoS One; 2014; 9(4):e93819. PubMed ID: 24699684
[TBL] [Abstract][Full Text] [Related]
15. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan.
Xu G; Zhang W; Ma MK; McLeod HL
Clin Cancer Res; 2002 Aug; 8(8):2605-11. PubMed ID: 12171891
[TBL] [Abstract][Full Text] [Related]
16. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect.
Merali Z; Ross S; Paré G
Drug Metabol Drug Interact; 2014; 29(3):143-51. PubMed ID: 24988246
[TBL] [Abstract][Full Text] [Related]
17. Carboxylesterase-2 is a highly sensitive target of the antiobesity agent orlistat with profound implications in the activation of anticancer prodrugs.
Xiao D; Shi D; Yang D; Barthel B; Koch TH; Yan B
Biochem Pharmacol; 2013 Feb; 85(3):439-47. PubMed ID: 23228697
[TBL] [Abstract][Full Text] [Related]
18. Involvement of human blood arylesterases and liver microsomal carboxylesterases in nafamostat hydrolysis.
Yamaori S; Fujiyama N; Kushihara M; Funahashi T; Kimura T; Yamamoto I; Sone T; Isobe M; Ohshima T; Matsumura K; Oda M; Watanabe K
Drug Metab Pharmacokinet; 2006 Apr; 21(2):147-55. PubMed ID: 16702735
[TBL] [Abstract][Full Text] [Related]
19. Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants.
Boberg M; Vrana M; Mehrotra A; Pearce RE; Gaedigk A; Bhatt DK; Leeder JS; Prasad B
Drug Metab Dispos; 2017 Feb; 45(2):216-223. PubMed ID: 27895113
[TBL] [Abstract][Full Text] [Related]
20. Differentiation of microsomal and cytosolic carboxylesterases in the rat liver by in vivo and in vitro inhibition.
Nousiainen U; Törrönen R
Gen Pharmacol; 1984; 15(3):223-7. PubMed ID: 6735136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
